Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia

Publisher Website
Google Scholar
Abstract
Between September 1986 and June 1997, 24 children with high-risk ALL in CR1 were allografted after TAM (fractionated TBI, high-dose Ara-C, and melphalan; n=10) or BAM protocol (busulfan, high-dose Ara-C, and melphalan; n=14). The EFS for transplants from sibling donors was 33% with TAM and 62% with BAM (P=0.148). The probability of acute GvHD was 70% with TAM and 15% with BAM (P=0.003). Four of 17 evaluable patients relapsed: one after TAM and three after BAM. In all, 46 other children transplanted in CR beyond CR1 were studied for sequelae. Long-term side effects were more frequent in TAM vs BAM. In children with ALL, busulfan may be a good alternative to TBI to improve the quality of life.

This publication has 29 references indexed in Scilit: